Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
Joint Authors
Chae, Hee Bok
Park, Seon Mee
Youn, Sei Jin
Source
Issue
Vol. 2013, Issue 2013 (31 Dec. 2013), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2013-06-05
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Medicine
Information Technology and Computer Science
Abstract EN
Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir.
Most clinical trials have examined DAAs in combination with standard of care (SOC) regimens.
Future therapeutic drugs were divided into three categories.
They are second-wave protease inhibitors, second-generation protease inhibitors, and polymerase inhibitors.
Second-wave protease inhibitors are more improved form and can be administered once a day.
Oral drug combinations can be favored because interferon (IFN) not only has to be given as intradermal injection, but also can cause several serious side effects.
Combination of drugs with different mechanisms shows a good sustained virological response (SVR).
But several mutations are associated with viral resistance to DAAs.
Therefore, genotypic resistance data may provide insights into strategies aimed at maximizing SVR rates and minimizing resistance.
Combined drug regimens are necessary to prevent the emergence of drug-resistant HCV.
Many promising DAA candidates have been identified.
Of these, a triple regimen containing sofosbuvir shows promise, and treatment with daclatasvir plus asunaprevir yields a high SVR rate (95%).
Oral drug combinations will be standard of care in the near future.
American Psychological Association (APA)
Chae, Hee Bok& Park, Seon Mee& Youn, Sei Jin. 2013. Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives. The Scientific World Journal،Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-1012757
Modern Language Association (MLA)
Chae, Hee Bok…[et al.]. Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives. The Scientific World Journal No. 2013 (2013), pp.1-9.
https://search.emarefa.net/detail/BIM-1012757
American Medical Association (AMA)
Chae, Hee Bok& Park, Seon Mee& Youn, Sei Jin. Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives. The Scientific World Journal. 2013. Vol. 2013, no. 2013, pp.1-9.
https://search.emarefa.net/detail/BIM-1012757
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1012757